In vivo fitness and virulence of a drug-resistant herpes simplex virus 1 mutant

Journal of General Virology

Volumn 88, Issue 5, 2007, Pages 1410-1414

  Pesola, Jean M ^a   Coen, Donald M ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; THIOUREA; THYMIDINE PHOSPHORYLASE; UNCLASSIFIED DRUG; VIRUS DNA; WAY 150138;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; BRAIN; EYE; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; HERPES SIMPLEX VIRUS 1; HERPES VIRUS INFECTION; IN VIVO STUDY; LETHAL MUTANT; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TRIGEMINUS GANGLION; VIRUS MUTATION; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; DNA, VIRAL; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; VARIATION (GENETICS); VIRULENCE; VIRUS REPLICATION;

ANIMALIA; HUMAN HERPESVIRUS 1; MUS;

EID: 34248144549     PISSN: 00221317     EISSN: None     Source Type: Journal    
DOI: 10.1099/vir.0.82787-0     Document Type: Article

References (31)

1. Bacon, T. H., Levin, M. J., Leary, J. J., Sarisky, R. T. & Sutton, D. (2003). Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 16, 114-128.
2. Bean, W. J., Threlkeld, S. C. & Webster, R. G. (1989). Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis 159, 1050-1056.
3. Chen, S. H., Cook, W. J., Grove, K. L. & Coen, D. M. (1998). Human thymidine kinase can functionally replace herpes simplex virus type 1 thymidine kinase for viral replication in mouse sensory ganglia and reactivation from latency upon explant. J Virol 72, 6710-6715.
4. Coen, D. M. (1994). Acyclovir-resistant, pathogenic herpesviruses. Trends Microbiol 2, 481-485.
5. Coen, D. M. & Richman, D. D. (2007). Antiviral agents. In Fields Virology, 5th edn, pp. 447-485. Edited by D. M. Knipe, P. M. Howley, D. E. Griffin, R. A. Lamb, M. A. Martin, B. Roizman & S. E. Straus. Philadelphia, PA: Lippincott Williams & Wilkins.
6. Coen, D. M. & Schaffer, P. A. (2003). Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat Rev Drug Discov 2, 278-288.
7. Coen, D. M., Irmiere, A. F., Jacobson, J. G. & Kerns, K. M. (1989). Low levels of herpes simplex virus thymidine-thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model. Virology 168, 221-231.
8. Desai, P., DeLuca, N. A. & Person, S. (1998). Herpes simplex virus type 1 VP26 is not essential for replication in cell culture but influences production of infectious virus in the nervous system of infected mice. Virology 247, 115-124.
9. Enquist, L. W., Husak, P. J., Banfield, B. W. & Smith, G. A. (1998). Infection and spread of alphaherpesviruses in the nervous system. Adv Virus Res 51, 237-347.
10. Field, H. J. & Coen, D. M. (1986). Pathogenicity of herpes simplex virus mutants containing drug resistance mutations in the viral DNA polymerase gene. J Virol 60, 286-289.
11. Jacobson, J., Kramer, M., Rozenberg, F., Hu, A. & Coen, D. M. (1995). Synergistic effects on ganglionic herpes simplex virus infections by mutations or drugs that inhibit the viral polymerase and thymidine kinase. Virology 206, 263-268.
12. Larder, B. A. & Darby, G. (1984). Virus drug-resistance: mechanisms and consequences. Antiviral Res 4, 1-42.
13. Leib, D. A., Coen, D. M., Bogard, C. L., Hicks, K. A., Yager, D. R., Knipe, D. M., Tyler, K. L. & Schaffer, P. A. (1989). Immediate-early regulatory gene mutants define different stages in the establishment and reactivation of herpes simplex virus latency. J Virol 63, 759-768.
14. Newcomb, W. W. & Brown, J. C. (2002). Inhibition of herpes simplex virus replication by WAY-150138: assembly of capsids depleted of the portal and terminase proteins involved in DNA encapsidation. J Virol 76, 10084-10088.
15. Newcomb, W. W., Juhas, R. M., Thomsen, D. R., Homa, F. L., Burch, A. D., Weller, S. K. & Brown, J. C. (2001). The UL6 gene product forms the portal for entry of DNA into the herpes simplex virus capsid. J Virol 75, 10923-10932.
16. Newcomb, W. W., Thomsen, D. R., Homa, F. L. & Brown, J. C. (2003). Assembly of the herpes simplex virus capsid: identification of soluble scaffold-portal complexes and their role in formation of portal-containing capsids. Virol 77, 9862-9871.
17. Oxford, J. S. & Potter, C. W. (1973). Aminoadamantane-resistant strains of influenza A2 virus. J Hyg (Lond) 71, 227-236.
18. Patel, A. H., Rixon, F. J., Cunningham, C. & Davison, A. J. (1996). Isolation and characterization of herpes simplex virus type 1 mutants defective in the UL6 gene. Virology 217, 111-123.
19. Pelosi, E., Mulamba, G. B. & Coen, D. M. (1998a). Penciclovir and pathogenesis phenotypes of drug-resistant herpes simplex virus mutants. Antiviral Res 37, 17-28.
20. Pelosi, E., Rozenberg, F., Coen, D. M. & Tyler, K. L. (1998b). A herpes simplex virus DNA polymerase mutation that specifically attenuates neurovirulence in mice. Virology 252, 364-372.
21. Pesola, J. M., Zhu, J., Knipe, D. M. & Coen, D. M. (2005). Herpes simplex virus 1 immediate-early and early gene expression during reactivation from latency under conditions that prevent infectious virus production. J Virol 79, 14516-14525.
22. Safrin, S., Elbeik, T., Phan, L., Robinson, D., Rush, J., Elbaggari, A. & Mills, J. (1994). Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 38, 1246-1250.
23. Sherman, G. & Bachenheimer, S. L. (1988). Characterization of intranuclear capsids made by is morphogenic mutants of HSV-1. Virology 163, 471-480.
24. Stevens, J. G. & Cook, M. L. (1971). Latent herpes simplex virus in spinal ganglia of mice. Science 173, 843-845.
25. Sweet, C., Hayden, F. G., Jakeman, K. J., Grambas, S. & Hay, A. J. (1991). Virulence of rimantadine-resistant human influenza A (H3N2) viruses in ferrets. J Infect Dis 164, 969-972.
26. Tenser, R. B. & Dunstan, M. E. (1979). Herpes simplex virus thymidine kinase expression in infection of the trigeminal ganglion. Virology 99, 417-422.
27. Tran, R. K., Lieu, P. T., Aguilar, S., Wagner, E. K. & Bloom, D. C. (2002). Altering the expression kinetics of VP5 results in altered virulence and pathogenesis of herpes simplex virus type 1 in mice. J Virol 76, 2199-2205.
28. Trus, B. L., Cheng, N., Newcomb, W. W., Homa, F. L., Brown, J. C. & Steven, A. C. (2004). Structure and polymorphism of the UL6 portal protein of herpes simplex virus type 1. J Virol 78, 12668-12671.
29. van Zeijl, M., Fairhurst, J., Jones, T. R., Vernon, S. K., Morin, J., LaRocque, J., Feld, B., O'Hara, B., Bloom, J. D. & Johann, S. V. (2000). Novel class of thiourea compounds that inhibit herpes simplex virus type 1 DNA cleavage and encapsidation: resistance maps to the UL6 gene. J Virol 74, 9054-9061.
30. Visalli, R. J. & van Zeiii, M. (2003). DNA encapsidation as a target for anti-herpesvirus drug therapy. Antiviral Res 59, 73-87.
31. Zhao, Z. S., Granucci, F., Yeh, L., Schaffer, P. A. & Cantor, H. (1998). Molecular mimicry by herpes simplex virus-type 1: autoimmune disease after viral infection. Science 279, 1344-1347.